Trial Search Results
Treatments for Insomnia: Mediators, Moderators and Quality of Life
The purpose of this study is to evaluate the relative efficacy and effectiveness of specific components of cognitive behavioral therapies for insomnia: sleep restriction (SR) and cognitive therapy (CT) in comparison to combined SR and CT (SR+CT).
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Palo Alto Veterans Institute for Research
Collaborator: National Institute of Mental Health (NIMH)
Stanford Investigator(s):
Intervention(s):
- Behavioral: Sleep Restriction
- Behavioral: Cognitive Behavioral Therapy
- Behavioral: Combined Therapy
Phase:
N/A
Eligibility
Inclusion Criteria:
- Males or females of any racial or ethnic group, aged 60 years old or older
- Independent living (not in nursing home, etc.)
- English-speaking
- Subjective complaint of insomnia associated with daytime impairment or distress
- DSM 5 (Diagnostic and Statistical Manual V) diagnosis of insomnia
- Score >10 on the Insomnia Severity Indexa
- Must live within 40 miles of Stanford University
Exclusion Criteria:
- Montreal Cognitive Assessment Scale <20
- Apnea-hypopnea index >10 or Periodic limb movement associated arousals > 5 per hour
- Use of medication specifically prescribed for sleep and unwilling or unable to
discontinue > one week prior to baseline data collection.
- Acute or unstable chronic illness: including but not limited to insulin dependent
diabetes (adult onset diabetes, controlled with oral medications or diet is
acceptable); uncontrolled thyroid disease, kidney, prostate or bladder conditions
causing excessively frequent urination (> 3 times per night); medically unstable
congestive heart failure, angina, other severe cardiac illness as defined by treatment
regimen changes in the prior 3 months; stroke with serious sequelae; cancer if < 1
year since end of treatment; asthma, emphysema, or other severe respiratory diseases
uncontrolled with medications; conditions associated with chronic pain such as
fibromyalgia; and neurological disorders such as Alzheimer's disease, Parkinson's
disease and unstable epilepsy as defined by treatment regimen changes in the prior 3
months.
- Use of CNS (central nervous system) active medications that would significantly impact
sleep or alertness is allowed as long as the dose, timing, and formulation are stable
(> 4 weeks).
- Excessive caffeine consumption (≥ three cups per day), excessive alcohol consumption
(> 14 drinks per week or > 4 drinks per occasion), or illicit substances (by
self-report).
- Major psychiatric diagnosis on Axis I of DSM-IV as tested by the Mini International
Neuropsychiatric Interview (Version 5.0).
- Lives more than 40 miles from Stanford University
Ages Eligible for Study
60 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting